A detailed history of Nuveen Asset Management, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 856,487 shares of LYEL stock, worth $522,457. This represents 0.0% of its overall portfolio holdings.

Number of Shares
856,487
Previous 843,257 1.57%
Holding current value
$522,457
Previous $1.22 Million 3.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $14,949 - $24,872
13,230 Added 1.57%
856,487 $1.18 Million
Q2 2024

Aug 09, 2024

SELL
$1.3 - $3.01 $11,437 - $26,481
-8,798 Reduced 1.03%
843,257 $1.22 Million
Q1 2024

May 13, 2024

BUY
$1.71 - $3.07 $209,586 - $376,274
122,565 Added 16.8%
852,055 $1.9 Million
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $2,457 - $4,154
-1,768 Reduced 0.24%
729,490 $1.42 Million
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $203,137 - $469,318
140,095 Added 23.7%
731,258 $1.07 Million
Q2 2023

Aug 14, 2023

BUY
$1.89 - $3.86 $271,345 - $554,176
143,569 Added 32.08%
591,163 $1.88 Million
Q1 2023

May 15, 2023

SELL
$1.97 - $3.58 $97,357 - $176,923
-49,420 Reduced 9.94%
447,594 $1.06 Million
Q4 2022

Feb 14, 2023

SELL
$2.78 - $8.09 $240,989 - $701,297
-86,687 Reduced 14.85%
497,014 $1.73 Million
Q3 2022

Nov 14, 2022

SELL
$5.54 - $8.27 $78,285 - $116,863
-14,131 Reduced 2.36%
583,701 $4.28 Million
Q2 2022

Aug 15, 2022

BUY
$3.68 - $6.8 $162,037 - $299,417
44,032 Added 7.95%
597,832 $3.9 Million
Q1 2022

May 16, 2022

BUY
$5.05 - $7.7 $2.43 Million - $3.7 Million
480,923 Added 659.91%
553,800 $2.83 Million
Q4 2021

Feb 14, 2022

BUY
$7.13 - $15.19 $193,073 - $411,330
27,079 Added 59.13%
72,877 $662,000
Q3 2021

Nov 12, 2021

BUY
$11.0 - $17.95 $503,778 - $822,074
45,798 New
45,798 $678,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.